These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21401458)

  • 1. Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia.
    Pignone MP; Flitcroft KL; Howard K; Trevena LJ; Salkeld GP; St John DJ
    Med J Aust; 2011 Feb; 194(4):180-5. PubMed ID: 21401458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.
    Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K
    PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
    Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal cancer screening in Australia: an economic evaluation of a potential biennial screening program using faecal occult blood tests.
    Stone CA; Carter RC; Vos T; John JS
    Aust N Z J Public Health; 2004 Jun; 28(3):273-82. PubMed ID: 15707175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria.
    Jahn B; Sroczynski G; Bundo M; Mühlberger N; Puntscher S; Todorovic J; Rochau U; Oberaigner W; Koffijberg H; Fischer T; Schiller-Fruehwirth I; Öfner D; Renner F; Jonas M; Hackl M; Ferlitsch M; Siebert U;
    BMC Gastroenterol; 2019 Dec; 19(1):209. PubMed ID: 31805871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The National Bowel Cancer Screening Program: time to achieve its potential to save lives.
    Ee H; St John J
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
    Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
    Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy.
    O'Leary BA; Olynyk JK; Neville AM; Platell CF
    J Gastroenterol Hepatol; 2004 Jan; 19(1):38-47. PubMed ID: 14675241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
    Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
    Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
    Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
    Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D
    PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of CT colonography for colorectal cancer screening on the UK NHS: costs, healthcare resources and health outcomes.
    Sweet A; Lee D; Gairy K; Phiri D; Reason T; Lock K
    Appl Health Econ Health Policy; 2011; 9(1):51-64. PubMed ID: 21174482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia.
    Salkeld G; Young G; Irwig L; Haas M; Glasziou P
    Aust N Z J Public Health; 1996 Apr; 20(2):138-43. PubMed ID: 8799087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of screening for colorectal cancer in the general population.
    Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
    JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test.
    Senore C; Hassan C; Regge D; Pagano E; Iussich G; Correale L; Segnan N
    J Med Screen; 2019 Jun; 26(2):76-83. PubMed ID: 30180780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation.
    Daniels K; McKee M
    J R Army Med Corps; 1995 Oct; 141(3):142-50. PubMed ID: 8568748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60-69 years.
    Lee D; Muston D; Sweet A; Cunningham C; Slater A; Lock K
    Appl Health Econ Health Policy; 2010; 8(3):141-54. PubMed ID: 20369905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential impact of population-based colorectal cancer screening in Canada.
    Flanagan WM; Le Petit C; Berthelot JM; White KJ; Coombs BA; Jones-McLean E
    Chronic Dis Can; 2003; 24(4):81-8. PubMed ID: 14733756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.